Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
5.13
Nov 19 • 3:59 PM ET Dollar change-0.19 Percentage change(-3.57%)
Aftermarket Close
5.04
Aftermarket • 7:30 PM ET Dollar change-0.09 Percentage change(-1.75%)
Index
RUT
Market Cap
402.43M
Enterprise Value
249.08M
Income
-99.14M
Sales
0.00M
Book/sh
1.68
Cash/sh
2.59
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
55
IPO
Jul 27, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
3.06
P/C
1.98
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
7.57
Current Ratio
7.57
Debt/Eq
0.38
LT Debt/Eq
0.37
Option/Short
Yes / Yes
EPS (ttm)
-1.49
EPS next Y
-1.51
EPS next Q
-0.32
EPS this Y
-79.55%
EPS next Y
-17.14%
EPS next 5Y
-25.73%
EPS past 3/5Y
-3.41% -3.52%
Sales past 3/5Y
- -
EPS Y/Y TTM
-171.31%
Sales Y/Y TTM
-
EPS Q/Q
-37.65%
Sales Q/Q
-
Insider Own
19.83%
Insider Trans
-2.00%
Inst Own
61.19%
Inst Trans
10.48%
ROA
-65.07%
ROE
-93.65%
ROIC
-54.80%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-34.57%
SMA50
-44.30%
SMA200
-38.90%
Trades
Shs Outstand
78.45M
Shs Float
62.89M
52W High
14.00 -63.36%
52W Low
4.35 17.93%
Volatility
13.46% 8.97%
ATR (14)
0.75
RSI (14)
26.39
Beta
-0.13
Rel Volume
0.93
Avg Volume
1.28M
Volume
1,190,304
Perf Week
-38.86%
Perf Month
-38.71%
Perf Quarter
-60.93%
Perf Half Y
-35.31%
Perf YTD
-9.20%
Perf Year
16.06%
Perf 3Y
470.00%
Perf 5Y
-52.81%
Perf 10Y
-
Prev Close
5.32
Price
5.13
Change %
-3.57%
Consensus
Strong Buy
Avg. Price Target
$17.67
Implied Upside
+244.4%
Analysts11incl. previous ratings
Rating Distribution11 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 22, 2026Initiated
JEF logoJJefferies
Buy$25+387.3%
Sep 21, 2026Upgrade
BAC logoBBofA Securities
Neutral → Buy$18+250.9%
Jul 13, 2026Initiated
SF logoSStifel
Buy$22+328.8%
Apr 20, 2026Initiated
CCantor Fitzgerald
Overweight
Oct 28, 2025Initiated
SStephens
Overweight$15+192.4%
Sep 03, 2025Downgrade
BAC logoBBofA Securities
Buy → Neutral$7+36.5%
Jun 30, 2025Resumed
HH.C. Wainwright
Buy$23+348.3%
Feb 20, 2025Initiated
C logoCCitigroup
Buy$25+387.3%
Feb 19, 2025Initiated
CCanaccord Genuity
Buy$20+289.9%
Feb 07, 2025Initiated
BAC logoBBofA Securities
Buy$15+192.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tak Paul PeterChief Executive OfficerSep 10 '26Option Exercise1.55125,000193,750393,566Sep 11 06:12 PM
Tak Paul PeterChief Executive OfficerSep 10 '26Sale11.50220,8662,539,893172,700Sep 11 06:12 PM
Tak Paul PeterChief Executive OfficerSep 11 '26Sale10.4659,379620,891113,321Sep 11 06:12 PM
PAUL PETER TAKDirectorSep 10 '26Proposed Sale12.17280,2453,410,582Sep 10 04:39 PM
Tyagarajan SeshuChief Technology OfficerAug 17 '26Sale12.007,00084,00076,865Aug 19 04:30 PM
SESHU TYAGARAJANOfficerAug 17 '26Proposed Sale11.727,00082,040Aug 17 04:37 PM
Barone FrancescaChief Scientific OfficerJun 29 '26Sale10.0623,447235,76977,362Jul 01 04:22 PM
Tyagarajan SeshuChief Technology OfficerJun 29 '26Sale10.027,00070,15183,865Jul 01 04:22 PM
SESHU P TYAGARAJANOfficerJun 29 '26Proposed Sale9.797,00068,530Jun 29 04:44 PM
FRANCESCA BARONEOfficerJun 29 '26Proposed Sale9.7923,447229,546Jun 29 04:41 PM
Manning Paul BDirectorFeb 23 '26Buy5.45550,4582,999,9962,763,527Feb 26 07:38 PM
Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
M.D.Dr. Paul-Peter Tak FOCIS
Senior VPMr. Charles Schoch
Ph.D.Dr. Francesca Barone M.D.
Chief Technical & Development OfficerDr. Seshu Tyagarajan Ph.D.
Vice President of Investor Relations & Business DevelopmentMr. Theodore Jenkins